The global artificial intelligence for drug discovery and development market size was valued at USD 2.4 billion in 2025 and is projected to grow from USD 3.12 billion in 2026 to USD 25.28 billion by 2034, registering a CAGR of 29.9% during the forecast period (2026–2034). North America dominated the artificial intelligence for drug discovery and development market with a market share of 41.5% in 2025.
Artificial intelligence for drug discovery and development focuses on using AI technologies to accelerate drug discovery, identify potential drug candidates, optimize clinical trials, and improve the efficiency of pharmaceutical research and development. Artificial intelligence for drug discovery and development are tracked under HSN Code 998113 (Research and Experimental Development Services in Medical Sciences and Pharmacy) and SIC Code 8731 (Commercial Physical and Biological Research).
Download a Free Sample To learn more about this report,
Integration of Generative AI for Novel Drug Molecule Design
Artificial intelligence for drug discovery and development market analysis shows that generative AI is shifting molecule design from conventional screening of existing compounds toward the creation of new molecules with targeted properties. These models can generate and optimize chemical structures based on desired biological activity, binding affinity, and safety characteristics, helping researchers identify promising drug candidates more efficiently. Insilico Medicine's AI-discovered drug candidate for idiopathic pulmonary fibrosis, rentosertib, demonstrates the application of generative AI in target identification and novel molecule development.
Adoption of AI-Based Protein Structure and Function Prediction
AI-based protein prediction is transitioning drug discovery from resource-intensive experimental analysis toward computational methods that estimate protein structures and identify potential functional relationships. These predictions help researchers understand disease-related proteins, identify binding sites, and guide the design of molecules that interact with specific biological targets. Google DeepMind's AlphaFold database has made predictions for more than 200 million protein structures publicly available, providing researchers with a valuable resource for drug target analysis and therapeutic research.
Demand for Faster Drug Candidate Screening and Availability of Biomedical and Chemical Datasets Drive Market
The need to shorten early-stage drug research creates demand for AI tools that screen large numbers of compounds more efficiently. AI systems can prioritize candidates based on biological activity, toxicity risks, and other drug-development criteria, helping researchers focus on the most promising options. Pharmaceutical companies can use virtual screening to narrow compound libraries before conducting costly laboratory experiments. Greater demand for faster and more efficient candidate assessment therefore supports adoption of AI in drug discovery and development.
The growing availability of biomedical and chemical datasets strengthens the supply of data resources needed to develop and train AI drug discovery tools. Large collections of molecular structures, biological assay results, and clinical information help algorithms identify patterns relevant to drug research. Resources such as PubChem provide researchers with extensive chemical information that can support compound analysis and computational drug screening. Broader access to structured research data therefore improves AI model development and supports growth in AI-driven drug discovery.
Limited Standardized Drug Discovery Data and Lack of AI Model Transparency Restrain Market Expansion
Limited availability of high-quality and standardized drug discovery data reduces the accuracy and reliability of AI models used to identify drug candidates and predict biological responses. Differences in data formats, experimental methods, and dataset completeness make it difficult to train models that perform consistently across research settings. As a result, unreliable predictions and additional data preparation requirements can slow adoption and restrict market growth.
Lack of Transparency in AI-Based Drug Prediction Models Lack of transparency in AI-based drug prediction models makes it difficult for researchers to understand how algorithms identify drug targets, predict molecular interactions, and assess potential therapeutic effects. This limited interpretability can reduce confidence in AI-generated results and increase the need for experimental verification before pharmaceutical companies use them in development decisions. Consequently, slower validation and cautious adoption can restrain market expansion.
AI in Clinical Trial Design, Patient Recruitment, and Drug Repurposing Offers Growth Opportunities
Pharmaceutical companies, contract research organizations, and clinical trial technology providers can use AI to improve protocol design, identify eligible participants, and support patient recruitment. Revenue avenues include AI-powered trial platforms, recruitment analytics, and subscription-based clinical research software. Companies such as IQVIA and Medidata offer technology solutions that support AI-enabled clinical trial planning and execution.
Pharmaceutical companies, biotechnology firms, and academic research institutions can use AI to identify new therapeutic uses for existing drugs and assess alternative treatment opportunities. Revenue avenues include drug repurposing platforms, licensing agreements, research partnerships, and computational evaluation services. Companies such as BenevolentAI and Insilico Medicine apply AI to drug discovery and therapeutic development, including opportunities involving existing compounds.
The drug optimisation and repurposing segment accounted for a share of 47.6% in 2025 owing to the ability of AI tools to identify new uses for existing drugs, optimize drug candidates, reduce development time, and improve research efficiency. The use of existing clinical and molecular data further supports faster candidate evaluation and more cost-efficient drug development.
The preclinical testing segment is expected to grow at a CAGR of 29.4% during the forecast period, driven by the increasing use of AI to predict drug toxicity, assess safety profiles, and accelerate compound screening before clinical trials.
Request Customizationto receive a tailored report.
The oncology segment accounted for a share of 38.7% in 2025 due to the extensive use of AI to identify drug targets, analyze tumor biology, and accelerate the development of cancer therapies. The growing complexity of cancer research and the need for targeted treatments further support the segment’s dominant market position.
The neurodegenerative diseases segment is expected to grow at a CAGR of 29.9% during the forecast period, fueled by the increasing use of AI to identify therapeutic targets, analyze complex disease mechanisms, and accelerate drug development for conditions such as Alzheimer’s and Parkinson’s disease.
The pharmaceutical & biotechnology segment accounted for a share of 61.8% in 2025, supported by substantial investments in drug research, extensive use of AI for compound screening and drug optimization, and strong capabilities in pharmaceutical development.
The CRO segment is expected to grow at a CAGR of 29.6% during the forecast period, propelled by the increasing outsourcing of drug discovery activities and the adoption of AI tools to accelerate compound screening, preclinical testing, and drug development.
Speak to an Analystto discuss market opportunities.
The North America artificial intelligence for drug Discovery and development market accounted for the largest regional share of 41.5% in 2025.
The U.S. Food and Drug Administration launched an information-gathering initiative in 2026 to explore how AI-enabled technologies can improve early-phase clinical trials, while the Department of Health and Human Services’ SURPASS program aims to accelerate clinical development through computational models, real-time analysis, and automation, supporting further adoption of AI in drug discovery and development.
Canada’s National Artificial Intelligence Strategy, launched in June 2026, targets increasing AI adoption among businesses from just over 12% to 60% by 2034 and generating an additional $200 billion in economic growth over five years, while the federal pharmaceutical and life sciences task force identifies AI-driven drug discovery as a growing sector strength, supporting future investment in AI-enabled pharmaceutical research.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific artificial intelligence for drug Discovery and development market is expected to grow at a CAGR of 32.4% during the forecast period 2026-2034, showcasing the fastest-growing regional market.
Japan’s government is promoting AI adoption in pharmaceutical research and development through initiatives supporting drug discovery and computational biology, while its goal of expanding the domestic biopharmaceutical and regenerative medicine market to ¥3.3 trillion by 2030 supports future demand for AI-enabled drug discovery technologies.
China aims to establish a preliminary integrated AI-driven drug regulation system by 2030, including high-quality datasets, specialized large AI models, and intelligent agents for drug review, approval, testing, and surveillance, strengthening the infrastructure supporting AI adoption across pharmaceutical development.
India’s BioE3 policy supports the establishment of Bio-AI hubs and biomanufacturing hubs to advance AI-enabled drug discovery and translational research, while the government targets a $300 billion bioeconomy by 2030, creating opportunities for AI-based pharmaceutical research and drug development.
The Europe artificial intelligence for drug Discovery and development market accounted for the regional share of 27.8% in 2025.
The U.K. government’s AI for Science Strategy targets the development of trial-ready drugs within 100 days by 2030, backed by up to £137 million for AI-enabled scientific research, while its Health Data Research Service is expected to provide access to AI-ready pathology, radiology, and genomic datasets by 2030, supporting wider adoption of AI in drug discovery and development.
Germany’s Federal Ministry of Research, Technology and Space is funding AI applications in drug discovery with up to €15 million from 2026 to 2029, covering six research collaborations and three individual projects involving 18 funding recipients, supporting the development of AI-based methods to accelerate drug discovery and improve research efficiency.
The artificial intelligence for drug discovery and development market is highly fragmented, with established pharmaceutical companies, technology providers and startups competing for market share. The competitive landscape is highly fragmented, with a mix of technology giants and specialized AI-driven drug discovery companies. Key players such as Alphabet Inc., NVIDIA Corporation, and Insilico Medicine Inc. are estimated to account for approximately 10–15% of the global market share, although this cumulative share is not independently verified.
Established players compete through advanced AI infrastructure, extensive datasets, research capabilities, and pharmaceutical partnerships. Emerging players focus on specialized algorithms, innovative drug discovery platforms, niche applications, cost efficiency, and faster development cycles. Technological innovation, model accuracy, scientific validation, and strategic collaborations remain key competitive factors.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Healthcare Human Resources Software Market Size, Share, 2034
Ai Based Clinical Trials Solution Provider Market Size, 2034
Meditation Management Apps Market Size, Share, Growth, Analysis, 2034
Digital Pathology Market Size, Share, Growth, Forecast, 2034
Digital Pills Market Size, Share, Growth, Analysis, Report, 2034
Healthcare Supply Chain Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com